Atherosclerosis can be partially reversed under the right conditions. Clinical trials have shown measurable plaque shrinkage when LDL cholesterol drops below 80 mg/dL, typically after about two years of aggressive treatment. The reversal is real but modest, and it depends heavily on plaque type, how far the disease has progressed, and how aggressively risk factors are managed.
What Reversal Actually Means
When researchers talk about reversing atherosclerosis, they don’t mean arteries returning to a pristine, disease-free state. They mean plaques getting smaller, more stable, and less likely to rupture and cause a heart attack. The body accomplishes this through several overlapping processes: pulling lipids out of the artery wall, clearing out dead cellular debris, thickening the fibrous cap that covers the plaque, and increasing calcification that stabilizes what remains.
The first step in plaque shrinkage is something called reverse cholesterol transport. Essentially, cholesterol that has been trapped inside artery-wall cells gets pulled out and shuttled to the liver for disposal. This process ramps up when blood levels of LDL cholesterol drop low enough. At the same time, the smooth muscle cells inside the plaque shift their behavior, producing more collagen and reinforcing the cap that sits over the fatty core. A thicker cap means the plaque is far less likely to crack open and trigger a clot.
The LDL Threshold for Shrinking Plaques
Not every degree of cholesterol lowering produces regression. A large meta-analysis of lipid-lowering trials found that plaque volume shrank significantly only when follow-up LDL levels fell below 80 mg/dL and HDL levels stayed above 45 mg/dL. Patients in the below-70 mg/dL group saw the most consistent regression. Those whose LDL remained above 100 mg/dL generally did not see their plaques shrink, even if they were on treatment.
This dual target matters. Lowering LDL alone may not be enough if HDL, which helps drive reverse cholesterol transport, stays low. The practical takeaway: the lower the LDL and the higher the HDL, the better the odds that existing plaques will stabilize and begin to recede.
How Long It Takes
Plaque regression is slow. A systematic review of trials that documented actual shrinkage found that it took an average of 19.7 months of aggressive lipid-lowering treatment before measurable regression appeared on imaging. This means you won’t see results from a cholesterol panel at your six-month checkup. Roughly two years of sustained, intensive treatment is the benchmark before expecting visible plaque changes, and researchers have suggested that patients stick with aggressive therapy for at least that long before considering any changes to their regimen.
Medications That Drive Regression
Statins remain the foundation. High-intensity statin therapy is the most studied approach for pushing LDL low enough to trigger regression, and decades of trial data support their role. But for many patients, statins alone don’t get LDL below 80 mg/dL.
That’s where newer drugs enter the picture. In the GLAGOV trial, adding a PCSK9 inhibitor (a type of injectable cholesterol-lowering medication) to statin therapy reduced plaque volume by 0.95%, while patients on statins plus placebo saw their plaques grow slightly. The difference was statistically significant and clinically meaningful, because even small reductions in plaque volume translate to meaningful drops in heart attack risk.
The 2026 ACC/AHA cholesterol guidelines now recommend layering additional medications on top of statins for high-risk patients who haven’t reached their LDL targets. These add-on options include cholesterol-absorption blockers and PCSK9 inhibitors. For patients with very high baseline cholesterol (190 mg/dL or above), the goal is to push LDL below 100 mg/dL even in the absence of established heart disease.
Lifestyle Changes and Plaque Regression
Medication isn’t the only path. The Lifestyle Heart Trial, led by Dean Ornish, put patients on an intensive program combining a very low-fat vegetarian diet (less than 10% of calories from fat), moderate aerobic exercise, stress management, and smoking cessation. After one year, artery blockages in the treatment group shrank by 1.75 percentage points. After five years, the improvement grew to 3.1 percentage points, representing a 7.9% relative improvement. Meanwhile, patients in the control group who followed conventional advice saw their blockages worsen.
These numbers are modest in absolute terms, but the direction matters enormously. The lifestyle group’s arteries were opening up while the control group’s arteries were closing down. The gap between the two widens over time. The catch is that the Ornish program is extremely strict. Most people find it difficult to sustain a diet that low in fat for years, which is why the majority of cardiologists combine moderate lifestyle changes with medication rather than relying on lifestyle alone.
Even without full-scale regression, exercise and dietary changes improve the composition of plaques, making them denser, more calcified, and less prone to rupture. A plaque that’s stable and shrinking slowly is far less dangerous than one that’s soft, inflamed, and growing.
Which Plaques Can Be Reversed
Not all plaques respond equally to treatment. Soft, lipid-rich plaques with large fatty cores are the most responsive to aggressive cholesterol lowering. These are also, not coincidentally, the most dangerous type because their thin caps are prone to rupture. When LDL drops dramatically, the cholesterol inside these plaques gets reabsorbed, the core shrinks, and the cap thickens.
Heavily calcified plaques are a different story. Calcification is actually a stabilizing process. These rock-hard deposits don’t rupture easily and don’t tend to shrink with treatment. In a sense, calcified plaques have already undergone a form of natural stabilization. They may narrow the artery, but they’re far less likely to cause a sudden heart attack. So while they’re resistant to regression, they’re also less of an acute threat.
When Reversal Isn’t Enough
For some patients, the disease has progressed too far for medical therapy alone to restore adequate blood flow. European cardiology guidelines identify several scenarios where bypass surgery is recommended over medical management alone. These include blockages greater than 50% in the left main coronary artery or the proximal section of the left anterior descending artery, multi-vessel disease combined with weakened heart function, and situations where a large area of the heart muscle (more than 10%) is starved of blood based on functional testing.
Patients with a single remaining open coronary artery that’s more than 50% blocked also typically need surgical intervention. In these cases, the risk of waiting for medical therapy to work is simply too high. The artery needs to be bypassed or opened mechanically before regression strategies can play a supporting role.
For patients with stable disease and less severe narrowing, optimized medical therapy performs well. Cardiac hospitalizations and mortality both drop with aggressive pharmacological management, and this is the population most likely to benefit from a regression-focused strategy.
Tracking Plaque Changes Over Time
Measuring whether plaques are actually shrinking requires specialized imaging. The gold standard is intravascular ultrasound, where a tiny probe is threaded inside the coronary artery during a catheterization. It provides highly detailed measurements of plaque volume but is invasive and expensive, so it’s used mainly in research settings.
CT coronary angiography is emerging as a noninvasive alternative. In head-to-head comparisons, CT scans correlated well with intravascular ultrasound for tracking plaque changes over time. Both methods agreed on whether plaques were progressing or regressing in the majority of cases. CT scans are more practical for routine monitoring, though the analysis currently takes significant time and expertise. For most patients outside of clinical trials, doctors track progress indirectly through LDL levels, symptoms, and periodic stress testing rather than serial plaque imaging.